The roles of phosphodiesterase 2 in the central nervous and peripheral systems

Current Pharmaceutical Design

Volumn 21, Issue 3, 2015, Pages 274-290

  Zhang, Chong ^a   Yu, Yingcong ^b   Ruan, Lina ^c   Wang, Chuang ^d   Pan, Jianchun ^c   Klabnik, Jonathan ^e   Lueptow, Lindsay ^e   Zhang, Han Ting ^e   O’Donnell, James M ^a   Xu, Ying ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b WENZHOU PEOPLE'S HOSPITAL   (China)

^c WENZHOU MEDICAL UNIVERSITY   (China)

^d NINGBO UNIVERSITY   (China)

^e WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Cardiovascular health; Cognition; Cyclic AMP (cAMP); Cyclic GMP (cGMP); Emotion; Phosphodiesterase 2 (PDE2); Respiratory health; Systemic infection

Indexed keywords

AMPA RECEPTOR; AMPHOTERICIN B; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIC GMP; ENZYME; FLUCONAZOLE; FLUCYTOSINE; MONOAMINE OXIDASE INHIBITOR; PHOSPHODIESTERASE 2; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; ROLIPRAM; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 2; PHOSPHODIESTERASE INHIBITOR;

ALZHEIMER DISEASE; ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; ARTICLE; BLOOD BRAIN BARRIER; CANDIDIASIS; CENTRAL NERVOUS SYSTEM; COGNITIVE DEFECT; DEPRESSION; ENDOTHELIUM CELL; HEART; HEART MUSCLE CELL; HUMAN; LEARNING DISORDER; MAJOR DEPRESSION; MEMORY; MEMORY DISORDER; NERVE CELL PLASTICITY; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; THROMBOCYTE; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; CENTRAL NERVOUS SYSTEM DISEASES; ENZYMOLOGY; METABOLISM; PERIPHERAL NERVOUS SYSTEM DISEASES;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 2; HUMANS; PERIPHERAL NERVOUS SYSTEM DISEASES; PHOSPHODIESTERASE INHIBITORS;

EID: 84925861030     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140826115245     Document Type: Article

References (193)

1. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: Essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007; 76: 481-511.
2. Feil S, Zimmermann P, Knorn A, et al. Distribution of cGMPdependent protein kinase type I and its isoforms in the mouse brain and retina. Neuroscience 2005; 135: 863-8.
3. Hofmann ME, Nahir B, Frazier CJ. Endocannabinoid-mediated depolarization-induced suppression of inhibition in hilar mossy cells of the rat dentate gyrus. J Neurophysiol 2006; 96: 2501-12.
4. Kleppisch T. Phosphodiesterases in the central nervous system. Handb Exp Pharmacol 2009; 191: 71-92.
5. Ashman DF, Lipton R, Melicow MM, et al. Isolation of adenosine 3’, 5'-monophosphate and guanosine 3', 5'-monophosphate from rat urine. Biochem Biophys Res Commun 1963; 11: 330-4.
6. Rall TW, Suther Land E W. Formation of a cyclic adenine ribonucleotide by tissue particles. J Biol Chem 1958; 232: 1065-76.
7. Sonnenburg WK, Mullaney PJ, Beavo JA. Molecular cloning of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase cDNA. Identification and distribution of isozyme variants. J Biol Chem 1991; 266: 17655-61.
8. Yang Q, Paskind M, Bolger G, et al. A novel cyclic GMP stimulated phosphodiesterase from rat brain. Biochem Biophys Res Commun 1994; 205: 1850-8.
9. Martins TJ, Mumby MC, Beavo JA. Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues. J Biol Chem 1982; 257: 1973-9.
10. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacol Rev 2006; 58: 488-520.
11. Huang D, Hinds TR, Martinez SE, Doneanu C, Beavo JA. Molecular determinants of cGMP binding to chicken cone photoreceptor phosphodiesterase. J Biol Chem 2004; 279: 48143-51.
12. Wu AY, Tang XB, Martinez SE, et al. Molecular determinants for cyclic nucleotide binding to the regulatory domains of phosphodiesterase 2A. J Biol Chem 2004; 279: 37928-38.
13. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacol Ther 2006; 109: 366-98.
14. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey replication. Arch Gen Psychiatry 2005; 62: 593-603.
15. Aan het Rot M, Mathew SJ, Charney DS. Neurobiological mechanisms in major depressive disorder. CMAJ 2009; 180: 305-13.
16. Caccia S. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 1998; 34: 281-302.
17. Covington H E, Vialou V, Nestler EJ. From synapse to nucleus: Novel targets for treating depression. Neuropharmacology 2010; 58: 683-93.
18. Esposito K, Reierson GW, Luo HR, et al. Phosphodiesterase genes and antidepressant treatment response: A review. Ann Med 2009; 41: 177-85.
19. Mathew SJ, Manji HK, Charney DS. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 2008; 33: 2080-92.
20. Alt Andrew, Nisenbaum ES, Bleakman D, et al. A role for AMPA receptors in mood disorders. Biochem Pharmacol 2006; 71: 1273-88.
21. Hebb ALO, Robertson HA. Role of phosphodiesterases in neurological and psychiatric disease. Curr Opin Pharmacol 2007; 7: 86-92.
22. O’Donnell J, Zhang H. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol Sci 2004; 25: 158-63.
23. Zhang HT, Huang Y, Jin SL, et al. Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology 2002; 27: 587-95.
24. Zhang HT, Zhao Y, Huang Y, et al. Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats. Psychopharmacology 2006; 186: 209-17.
25. Zeller E, Stief HJ, Pflug B, et al. Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry 1984; 17: 188-90.
26. Burgin AB, Magnusson OT, Singh J, et al. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol 2010; 28: 63-70.
27. Lakics V, Karran EH, Boess FG. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 2010; 59: 367-74.
28. Benes FM, Vincent SL, Todtenkopf M. The density of pyramidal and nonpyramidal neurons in anterior cingulate cortex of schizophrenic and bipolar subjects. Biol Psychiatry 2001; 50: 395-406.
29. Conti AC, Blendy JA. Regulation of Antidepressant Activity by cAMP Response Mol Neurobiol 2004; 30: 143-55.
30. Hoeffler JP, Meyer TE, Yun Y, et al. Cyclic AMP-responsive DNA-binding protein: Structure based on a cloned placental cDNA. Science 1988; 242: 1430-3.
31. Castrén E. Neurotrophic effects of antidepressant drugs. Curr Opin Pharmacol 2004; 4: 58-64.
32. Shaywitz AJ, Greenberg ME. CREB: A stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 1999; 68: 821-61.
33. Dwivedi Y, Pandey GN. Adenylyl cyclase-cyclicAMP signaling in mood disorders: Role of the crucial phosphorylating enzyme protein kinase A. Neuropsychiatr Dis Treat 2008; 4: 161-76.
34. Yamada S, Yamamoto M, Ozawa H, et al. Reduced phosphorylation of cyclic AMP-responsive element binding protein in the postmortem orbitofrontal cortex of patients with major depressive disorder. J Neural Transm 2003; 110: 671-80.
35. D’Sa C, Duman RS. Antidepressants and neuroplasticity. Bipolar Disord 2002; 4: 183-94.
36. Dash PK, Karl KA, Colicos MA, et al. cAMP response elementbinding protein is activated by Ca2+/calmodulin-as well as cAMPdependent protein kinase. Proc Natl Acad Sci USA 1991; 88: 5061-5.
37. Sheng M, Thompson M A, Greenberg M E. CREB: A Ca(2+)-regulated transcription factor phosphorylated by calmodulindependent kinases. Science 1991; 252: 1427-30.
38. Sun P, Enslen H, Myung P S, et al. Differential activation of CREB by Ca2+/calmodulin-dependent protein kinases type II and type IV involves phosphorylation of a site that negatively regulates activity. Genes Dev 1994; 8: 2527-39.
39. Nestler E J, Barrot M, DiLeone R J, et al. Neurobiology of depression. Neuron 2002; 34: 13-25.
40. Saarelainen T, Hendolin P, Lucas G, et al. Activation of the Trk B neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci 2003; 23: 349-57.
41. Conti A C, Cryan J F, Dalvi A, et al. cAMP response elementbinding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci 2002; 22: 3262-8.
42. Menniti F S, Faraci W S, Schmidt C J. Phosphodiesterases in the CNS: Targets for drug development. Nat Rev Drug Discov 2006; 5: 660-70.
43. Boess F G, Hendrix M, Van der, Staay, et al. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 2004; 47: 1081-92.
44. Xu Y, Pan J, Chen L, et al. Phosphodiesterase-2 inhibitor reverses corticosterone-induced neurotoxicity and related behavioural changes via cGMP/PKG dependent pathway. Int J Neuropsychopharmacol 2013; 16: 835-47.
45. Malenka R C, Nicoll R A. Long-term potentiation--a decade of progress. Science 1999; 285: 1870-4.
46. Alt A, Witkin J M, Bleakman D. AMPA receptor potentiators as novel antidepressants. Curr Pharm Des 2005; 11: 1511-27.
47. Duman R S, Heninger G R, Nestler E J. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997; 54: 597-606.
48. Hayashi T, Umemori H, Mishina M, et al. The AMPA receptor interacts with and signals through the protein tyrosine kinase Lyn. Nature 1999; 397: 72-6.
49. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol 2006; 27: 24-31.
50. Maes M, Bosmans E, Meltzer H Y, et al. Interleukin-1 beta: A putative mediator of HPA axis hyperactivity in major depression. Am J Psychiatry 1993; 150: 1189-93.
51. Bierhaus A, Wolf J, Andrassy M, et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci USA 2003; 100: 1920-5.
52. Essayan D M. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 2001; 108: 671-80.
53. Seybold J, Thomas D, Witzenrath M, et al. Tumor necrosis factoralpha-dependent expression of phosphodiesterase 2: Role in endothelial hyperpermeability. Blood 2005; 105: 3569-76.
54. Gustafsson AB, Brunton LL. Attenuation of cAMP accumulation in adult rat cardiac fibroblasts by IL-1beta and NO: Role of cGMPstimulated PDE2. Am J Physiol Cell Physiol 2002; 283: C463-71.
55. Domek-Łopacińska K, Strosznajder J B. Cyclic GMP metabolism and its role in brain physiology. J Physiol Pharmacol 2005; 56: 15-34.
56. Lein ES, Hawrylycz MJ, Ao N, et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature 2007; 445: 168-76.
57. Gur TL, Conti AC, Holden J, et al. cAMP response elementbinding protein deficiency allows for increased neurogenesis and a rapid onset of antidepressant response. J Neurosci 2007; 27: 7860-8.
58. Corbin J D, Turko I V, Beasley A, et al. Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem 2000; 267: 2760-7.
59. Liu X, Liu TT, Bai WW, Yi H, Li SY, Tian X. Encoding of rat working memory by power of multi-channel local field potentials via sparse non-negative matrix factorization. Neurosci Bull 2013; 29: 279-86.
60. Snyder P B, Florio V A, Ferguson K, et al. Isolation, expression and analysis of splice variants of a human Ca2+/calmodulinstimulated phosphodiesterase (PDE1A). Cellular signal 1999; 11: 535-44.
61. Fujishige K, Kotera J, Omori K. Striatum-and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A. Eur J Biochem 1999; 266: 1118-27.
62. Wang L, Gang Zhang Z, Lan Zhang R, et al. Activation of the PI3-K/Akt pathway mediates cGMP enhanced-neurogenesis in the adult progenitor cells derived from the subventricular zone. J Cereb Blood Flow Metab 2005; 25: 1150-8.
63. American Psychiatric Association Task Force On DSM-IV. Diagnostic and statistical manual of mental disorders: DSM-IV-TR (p. 943). American Psychiatric Pub.
64. Crisp A, Gelder M, Goddard E, et al. Stigmatization of people with mental illnesses: A follow-up study within the Changing Minds campaign of the Royal College of Psychiatrists. World Psychiatry 2005; 4: 106-13.
65. Kessler R C, Chiu W T, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 617-27.
66. Ravindran L N, Stein M B. The pharmacologic treatment of anxiety disorders: A review of progress. J Clin Psychiatry 2010; 71: 839-54.
67. Huh J, Goebert D, Takeshita J. et al. Treatment of generalized anxiety disorder: A comprehensive review of the literature for psychopharmacologic alternatives to newer antidepressants and benzodiazepines. Prim Care Companion CNS Disord 2011; 13: 709.
68. Beer B, Chasin M, Clody D E, et al. Cyclic adenosine monophosphate phosphodiesterase in brain: Effect on anxiety. Science 1972; 176: 428-30.
69. Barton M B, Morley D S, Moore S. et al. Decreasing women’s anxieties after abnormal mammograms: A controlled trial. J J Natl Cancer Inst 2004; 96: 529-38.
70. Nikolaev V O, Gambaryan S, Engelhardt S. et al. Real-time monitoring of the PDE2 activity of live cells: Hormone-stimulated cAMP hydrolysis is faster than hormone-stimulated cAMP synthesis. J Biol Chem 2005; 280: 1716-9.
71. Wang, C, Wang, R, & Xu, Y. 2013; CHAPTER 9.
72. Arranz L, Guayerbas N, De la Fuente M. Impairment of several immune functions in anxious women. J Psychosom Res 2007; 62: 1-8.
73. Bouayed J, Rammal H, Younos C, et al. Positive correlation between peripheral blood granulocyte oxidative status and level of anxiety in mice. Eur J Pharmacol 2007; 564: 146-9.
74. Kuloglu M, Atmaca M, Tezcan E. et al. Antioxidant enzyme activities and malondialdehyde levels in patients with obsessivecompulsive disorder. Neuropsychobiology 2002; 46: 27-32.
75. Masood A, Huang Y, Hajjhussein H. et al. Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling. J Pharmacol Exp Ther 2009; 331: 690-9.
76. Masood A, Nadeem A, Mustafa SJ. et al. Reversal of Oxidative Stress-Induced Anxiety by Inhibition of Phosphodiesterase-2 in Mice. J Pharmacol Exp Ther 2008; 326: 369-79.
77. Abel T, Lattal K M. Molecular mechanisms of memory acquisition, consolidation and retrieval. Curr Opin Neurobiol 2001; 11: 180-7.
78. Rolls E T, Dempere-Marco L, Deco G. Holding multiple items in short term memory: A neural mechanism. PloS one 2013; 8: E61078.
79. Kang S, Ling Q L, Liu W T, et al. Down-regulation of dorsal striatal RhoA activity and impairment of working memory in middleaged rats. Neurobiol Learn Mem 2103; 103: 3-10.
80. Reierson G W, Guo S, Mastronardi C, et al. cGMP Signaling, Phosphodiesterases and Major Depressive Disorder. Curr Neuropharmacol 2011; 9: 715-27.
81. Serrano F, Klann E. Reactive oxygen species and synaptic plasticity in the aging hippocampus. Ageing Res Rev 2004; 3: 431-43.
82. Puzzo D, Sapienza S, Role of phosphodiesterase 5 in synaptic plasticity and memory Neuropsychiatr Dis Treat 2008; 4: 371-87.
83. García-Osta A, Cuadrado-Tejedor M, García-Barroso C, et al. Phosphodiesterases as therapeutic targets for Alzheimer’s disease. ACS Chem Neurosci 2012; 3: 832-44.
84. Sierksma A S R, Rutten K, Sydlik S, et al. Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer’s disease. Neuropharmacology 2013; 64: 124-36.
85. Mohs RC. A perspective on risks that impede development of drugs to modify the course of Alzheimer’s disease: Can they be reduced? Alzheimers Dement 2008; 4: S85-87.
86. Lopez OL, Becker JT, Wahed A S, et al. NIH Public Access 2010; 80: 600-7.
87. Mehta M, Adem A, Sabbagh M. New acetylcholinesterase inhibitors for Alzheimer’s disease. Int J Alzheimers Dis 2012; 2012: 728983.
88. Domek-Łopacińska KU, Strosznajder JB. Cyclic GMP and nitric oxide synthase in aging and Alzheimer’s disease. Mol Neurobiol 2010; 41: 129-37.
89. Vitolo O V, Sant’Angelo A, Costanzo V, et al. Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: Reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci USA 2002; 99: 13217-21.
90. Eckert A, Nisbet R, Grimm A, Götz J. March separate, strike together-Role of phosphorylated TAU in mitochondrial dysfunction in Alzheimer’s disease. Biochim Biophys Acta 2013; 39: 282
91. Taylor SS, Zhang P, Steichen JM, Keshwani MM, Kornev AP. PKA: Lessons learned after twenty years. Biochim Biophys Acta 2013; 1834: 1271-8.
92. Nguyen P V, Woo NH. Regulation of hippocampal synaptic plasticity by cyclic AMP-dependent protein kinases. Prog Neurobiol 2003; 71: 401-37.
93. Guan J, Su S C, Gao J, et al. Cdk5 Is Required for Memory Function and Hippocampal Plasticity via the cAMP Signaling Pathway. PloS one 2011; 6: 25735.
94. Chen Y, Cai R. Study and analytical application of inhibitory effect of captopril on multienzyme redox system. Talanta 2003; 61: 855-61.
95. Sanderson TM, Sher E. The role of phosphodiesterases in hippocampal synaptic plasticity. Neuropharmacology 2013; 74: 86-95.
96. Diebold I, Djordjevic T, Petry A, et.al. Phosphodiesterase 2 mediates redox-sensitive endothelial cell proliferation and angiogenesis by thrombin via Rac1 and NADPH oxidase 2. Circ Res 2009; 104: 1169-77.
97. Gong B, Vitolo OV, Trinchese F, et al. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest 2004; 114: 1624-34.
98. Patel VP, Chu CT. Nuclear transport, oxidative stress, and neurodegeneration. Int J Clin Exp Pathol 2011; 4: 215-29.
99. Titus DJ, Sakurai A, Kang Y, et al. Phosphodiesterase Inhibition Rescues Chronic Cognitive Deficits Induced by Traumatic Brain Injury. J Neurosci 2013; 33: 5216-26.
100. [100] Kishida KT, Klann E. Sources and targets of reactive oxygen species in synaptic plasticity and memory. Antioxid Redox Signal 2007; 9: 233-44.
101. [101] Mseeh F, Colman RF, Colman RW. Inactivation of platelet PDE2 by an affinity label: 8-[(4-bromo-2, 3-dioxobutyl)thio]cAMP. Thromb Res 2000; 98: 395-401.
102. [102] Ma T, Du X, Pick JE, et al. Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer’s disease model mice. T J Neurosci 2012; 32: 13701-4708.
103. [103] Gourlay CW, Ayscough KR. Identification of an upstream regulatory pathway controlling actin-mediated apoptosis in yeast. J Cell Sci 2005; 118: 2119-32
104. [104] Shelat PB, Chalimoniuk M, Wang JH, et al. Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons. J Neurochem 2008; 106: 45-55.
105. [105] Reierson GW, Guo S, Mastronardi C, Licinio J, Wong M-L. cGMP Signaling, Phosphodiesterases and Major Depressive Disorder. Curr Neuropharmacol 2011; 9: 715-27.
106. [106] Cheng A, Hou Y, Mattson MP. Mitochondria and neuroplasticity. ASN Neuro 2010; 2: 243-56.
107. [107] Du H, Guo L, Wu X, et al. Biochimica et Biophysica Acta Cyclophilin D deficiency rescues Aβ-impaired PKA/CREB signaling and alleviates synaptic degeneration. Biochim Biophys Acta 2013; 4439: 78-81
108. [108] Cao X, Zhao S, Liu D, et al. Chemico-Biological Interactions ROSCa 2 + is associated with mitochondria permeability transition pore involved in surfactin-induced MCF-7 cells apoptosis 2011; 190: 16-27.
109. [109] Ermak G, Davies KJA. Calcium and oxidative stress: From cell signaling to cell death. Mol Immunol 2001; 38: 713-21.
110. [110] Goraya TA, Cooper DMF. Ca2+-calmodulin-dependent phosphodiesterase (PDE1): Current perspectives. Cellular signal 2005; 17: 789-97.
111. [111] Willoughby D, Cooper DMF. Organization and Ca2+ regulation of adenylyl cyclases in cAMP microdomains. Physiol Rev 2007; 87: 965-1010.
112. [112] Zhang W, Tingare A, Ng DC, et al. IP 3-dependent intracellular Ca 2 + release is required for cAMP-induced c-fos expression in hippocampal neurons. Biochem Biophys Res Commun 2012; 425: 450-5.
113. [113] Duszczyk M, Kuszczyk M, Guridi M, et al. In vivo hippocampal microdialysis reveals impairment of NMDA receptor-cGMP signaling in APP (SW) and APP (SW)/PS1 (L166P) Alzheimer’s transgenic mice. Neurochem Int 2012; 61: 976-80.
114. [114] Kleppisch T, Feil R. cGMP signalling in the mammalian brain: Role in synaptic plasticity and behaviour. Handb Exp Pharmacol 2009; 191: 549-79.
115. [115] Calabrese V, Mancuso C, Calvani M, et al. Nitric oxide in the central nervous system: Neuroprotection versus neurotoxicity. Nat Rev Neurosci 2007; 8: 766-75.
116. [116] Ferris CD, Cameron AM, Bredt DS, et al. Inositol 1, 4, 5-trisphosphate receptor is phosphorylated by cyclic AMP-dependent protein kinase at serines 1755 and 1589. Biochem Biophys Res Commun 1991; 175: 192-8.
117. [117] Reyes-Irisarri E, Markerink-Van Ittersum M, Mengod G, et al. Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer’s disease human brains. Eur J Neurosci 2007; 25: 3332-8.
118. [118] Gallo EF, Iadecola C. Neuronal nitric oxide contributes to neuroplasticity-associated protein expression through cGMP, protein kinase G, and extracellular signal-regulated kinase. J Neurosci 2011; 31: 6947-55.
119. [119] Ota KT, Pierre V J, Ploski JE. The NO-cGMP-PKG signaling pathway regulates synaptic plasticity and fear memory consolidation in the lateral amygdala via activation of ERK/MAP kinase. Learn Mem 2008; 15: 792-805.
120. [120] Rutten K, Prickaerts J, Hendrix M, et al. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: Studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. Eur J Pharmacol 2007; 558: 107-12.
121. [121] Reneerkens OaH, Rutten K, Bollen E, et al. Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801. Behav Brain Res 2013; 236: 16-22.
122. [122] Reneerkens OAH, Rutten K, Steinbusch HWM, et al. Selective phosphodiesterase inhibitors: A promising target for cognition enhancement. Psychopharmacology (Berl) 2009; 202: 419-43.
123. [123] Puzzo D, Vitolo O, Trinchese F, et al. Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive elementbinding protein pathway during hippocampal synaptic plasticity. J Neurosci 2005; 25: 6887-97.
124. [124] Puzzo D, Staniszewski A, Deng SX, et al. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer’s disease mouse model. J Neurosci 2009; 29: 8075-86.
125. [125] Bonkale WL, Winblad B, Ravid R, et al. Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer’s disease. Neurosci Lett 1995; 187: 5-8.
126. [126] Francis SH, Busch JL, Corbin JD, et al. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev 2010; 62: 525-63.
127. [127] Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther 2009; 122: 216-38.
128. [128] Fischmeister R, Castro L, Abi-Gerges A, et al. Species-and tissuedependent effects of NO and cyclic GMP on cardiac ion channels. Comp Biochem Physiol A Mol Integr Physiol 2005; 142: 136-143.
129. [129] Mokni W, Keravis T, Etienne-Selloum N, et al. Concerted Regulation of cGMP and cAMP Phosphodiesterases in Early Cardiac Hypertrophy Induced by Angiotensin II. PLoS ONE 2010; 5: E14227.
130. [130] Yanaka N, Kurosawa Y, Minami K, et al. cGMP-phosphodiesterase activity is up-regulated in response to pressure overload of rat ventricles. Biosci Biotechnol Biochem 2003; 67: 973-9.
131. [131] Castro LRV. Cyclic Guanosine Monophosphate Compartmentation in Rat Cardiac Myocytes. Circulation 2006; 113: 2221-8.
132. [132] Knight, WE, Yan C. Cardiac cyclic nucleotide phosphodiesterases: Function, regulation, and therapeutic prospects. Horm Metab Res 2012; 44: 766-75.
133. [133] Rybin VO, Xu X, Lisanti MP, et al. Differential targeting of beta-adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway. J Biol Chem 2000; 275: 41447-57.
134. [134] Buxton IL, Brunton LL. Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes. J Biol Chem 1983; 258: 10233-9.
135. [135] Jurevicius J, Fischmeister R. cAMP compartmentation is responsible for a local activation of cardiac Ca2+ channels by betaadrenergic agonists. Proc Natl Acad Sci USA 1996; 93: 295-9.
136. [136] Zaccolo M, Pozzan T. Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science 2002; 295: 1711-5.
137. [137] Kapiloff MS. Contributions of protein kinase A anchoring proteins to compartmentation of cAMP signaling in the heart. Mol Pharmacol 2002; 62: 193-9.
138. [138] Méry PF, Lohmann SM, Walter U, et al. Ca2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Proc Natl Acad Sci USA 1991; 88: 1197-201.
139. [139] Méry PF, Pavoine C, Belhassen L, et al. Nitric oxide regulates cardiac Ca2+ current. Involvement of cGMP-inhibited and cGMPstimulated phosphodiesterases through guanylyl cyclase activation. J Biol Chem 1993; 268: 26286-95.
140. [140] Rivet-Bastide M, Vandecasteele G, Hatem S, Verde I, Bénardeau A, Mercadier JJ, et al. cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes. J Clin Invest 1997; 99: 2710-8.
141. [141] Han X, Kobzik L, Balligand J L, et al. Nitric oxide synthase (NOS3)-mediated cholinergic modulation of Ca2+ current in adult rabbit atrioventricular nodal cells. Circ Res 1996; 78: 998-1008.
142. [142] Mongillo M, Tocchetti C G, Terrin A, et al. Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res 2006; 98: 226-34.
143. [143] Weninger S, De Maeyer JH, Lefebvre RA, et al. Study of the regulation of the inotropic response to 5-HT4 receptor activation via phosphodiesterases and its cross-talk with C-type natriuretic peptide in porcine left atrium. Naunyn Schmiedebergs Arch Pharmacol 2012; 385: 565-77.
144. [144] Miao L, Wang M, Yin W X, et al. Atrial natriuretic peptide regulates Ca channel in early developmental cardiomyocytes. PloS one 2010; 5: E8847.
145. [145] Mohamed T M, a Oceandy D, Zi M, et al. Plasma membrane calcium pump (PMCA4)-neuronal nitric-oxide synthase complex regulates cardiac contractility through modulation of a compartmentalized cyclic nucleotide microdomain. J Biol Chem 2011; 286: 41520-9.
146. [146] Houslay M D, Milligan G. Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biochem Sci 1997; 22: 217-24.
147. [147] Rochais F, Vandecasteele G, Lefebvre F, et al. Negative feedback exerted by cAMP-dependent protein kinase and cAMP phosphodiesterase on subsarcolemmal cAMP signals in intact cardiac myocytes: An in vivo study using adenovirus-mediated expression of CNG channels. J Biol Chem 2004; 279: 52095-105.
148. [148] Bloom TJ. Cyclic nucleotide phosphodiesterase isozymes expressed in mouse skeletal muscle. Can J Physiol Pharmacol 2002; 80: 1132-5
149. [149] Bloom TJ. Age-related alterations in cyclic nucleotide phosphodiesterase activity in dystrophic mouse leg muscle. Can J Physiol Pharmacol 2005; 83: 1055-60
150. [150] Del Zoppo G J. The role of platelets in ischemic stroke. Neurology 1998; 51: S9-14.
151. [151] Iffland A, Kohls D, Low S, et al. Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system. Biochemistry 2005; 44: 8312-25.
152. [152] Walter U, Gambaryan S. cGMP and cGMP-dependent protein kinase in platelets and blood cells. Handb Exp Pharmacol 2009; 191: 533-48.
153. [153] Rondina M T, Lam U T, Pendleton R C, et al. (18)F-FDG PET in the evaluation of acuity of deep vein thrombosis. Clin Nucl Med 2012; 37: 1139-45.
154. [154] Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: Phosphodiesterase inhibitors. Br J Clin Pharmacol 2011; 72: 634-46.
155. [155] Hidaka H, Asano T. Human blood platelet 3’: 5'-cyclic nucleotide phosphodiesterase. Isolation of low-Km and high-Km phosphodiesterase. Biochim Biophys Acta 1976; 429: 485-97.
156. [156] Valant P A, Haynes D H. The Ca (2+)-extruding ATPase of the human platelet creates and responds to cytoplasmic pH changes, consistent with a 2 Ca2+/nH+ exchange mechanism. J Membr Biol 1993; 136: 215-30.
157. [157] Jiang H, Shabb J B, Corbin J D. Cross-activation: Overriding cAMP/cGMP selectivities of protein kinases in tissues. Biochem Cell Biol 1992; 70: 1283-9.
158. [158] Tang K M, Sherwood J L, Haslam R J. Photoaffinity labelling of cyclic GMP-binding proteins in human platelets. Biochem J 1993; 294: 329-33.
159. [159] Horstrup K, Jablonka B, Hönig-Liedl P, et al. Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition. Eur J Biochem 1994; 225: 21-7.
160. [160] Dickinson N T, Jang E K, Haslam R J. Activation of cGMPstimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: Effects on platelet aggregation. Biochem J 1997; 323: 371-7.
161. [161] Jensen B O, Selheim F, Døskeland S O, et al. Protein kinase A mediates inhibition of the thrombin-induced platelet shape change by nitric oxide. Blood 2004; 104: 2775-82.
162. [162] Brito F C F, Kummerle A E, Lugnier C, et al. Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition. Eur J Biochem 2010; 638: 5-12.
163. [163] Yi S, Sahni N, Daniels KJ, et al. Alternative mating type configurations (a/αversus a/a or α/α) of Candida albicans result in alternative biofilms regulated by different pathways. PLoS Biol 2011; 9: E1001117.
164. [164] Garcia JG, Verin AD, Schaphorst KL. Regulation of thrombinmediated endothelial cell contraction and permeability. Semin Thromb Hemost 1996; 22: 309-15.
165. [165] Hippenstiel S, Witzenrath M, Schmeck B, et al. Adrenomedullin reduces endothelial hyperpermeability. Circ Res 2002; 91: 618-25.
166. [166] Petrache I, Verin AD, Crow MT, Birukova A, Liu F, Garcia JG. Differential effect of MLC kinase in TNF-alpha-induced endothelial cell apoptosis and barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 2001; 280: L1168-78.
167. [167] Stevens T, Creighton J, Thompson WJ. Control of cAMP in lung endothelial cell phenotypes. Implications for control of barrier function. Am J Physiol 1999; 277: L119-26.
168. [168] Surapisitchat J, Jeon K-I, Yan C, Beavo JA. Differential regulation of endothelial cell permeability by cGMP via phosphodiesterases 2 and 3. Circ Res 2007; 101: 811-818.
169. [169] Witzenrath M, Gutbier B, Schmeck B, et al. Phosphodiesterase 2 inhibition diminished acute lung injury in murine pneumococcal pneumonia. Crit Care Med 2009; 37: 584-90.
170. [170] Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000; 342: 1334-49.
171. [171] Lo H J, Köhler J R, DiDomenic B, et al. Nonfilamentous C. albicans mutants are avirulent. Cell 1997; 90: 939-49.
172. [172] Naglik J R, Fostira F, Ruprai J, et al. Candida albicans HWP1 gene expression and host antibody responses in colonization and disease. J Med Microbiol 2006; 55: 1323-7.
173. [173] Cao YY, Cao YB, Xu Z, et al. cDNA microarray analysis of differential gene expression in Candida albicans biofilm exposed to farnesol. Antimicrob Agents Chemother 2005; 49: 584-9.
174. [174] Georgopapadakou N H. Antifungals: Mechanism of action and resistance, established and novel drugs. Curr Opin Microbiol 1998; 1: 547-57.
175. [175] Vanden Bossche H, Dromer F, Improvisi I, et al. Antifungal drug resistance in pathogenic fungi. Med Mycol 1998; 36: 119-28.
176. [176] Lengeler K B, Davidson R C, D’souza C, et al. Signal transduction cascades regulating fungal development and virulence. Microbiol Mol Biol Rev 2000; 64: 746-85.
177. [177] Wilson D, Fiori A, Brucker K De, et al. Candida albicans Pde1p and Gpa2p comprise a regulatory module mediating agonistinduced cAMP signalling and environmental adaptation. Fungal Genet Biol 2010; 47: 742-52.
178. [178] Rocha C R, Schröppel K, Harcus D, et al. Signaling through adenylyl cyclase is essential for hyphal growth and virulence in the pathogenic fungus Candida albicans. Mol Biol Cell 2001; 12: 3631-43.
179. [179] Bahn YS, Sundstrom P. CAP1, an adenylate cyclase-associated protein gene, regulates bud-hypha transitions, filamentous growth, and cyclic AMP levels and is required for virulence of Candida albicans. J Bacteriol 2001; 183: 3211-23.
180. [180] Feng Q, Summers E, Guo B, et al. Ras signaling is required for serum-induced hyphal differentiation in Candida albicans. J Bacteriol 1999; 181: 6339-46.
181. [181] Braun B R, Johnson A D. TUP1, CPH1 and EFG1 make independent contributions to filamentation in candida albicans. Genetics 2000; 155: 57-67.
182. [182] Doedt T, Krishnamurthy S, Bockmühl D P, et al. APSES proteins regulate morphogenesis and metabolism in Candida albicans. Mol Biol Cell 2004; 15: 3167-80.
183. [183] Tebarth B, Doedt T, Krishnamurthy S, et al. Adaptation of the Efg1p morphogenetic pathway in Candida albicans by negative autoregulation and PKA-dependent repression of the EFG1 gene. J Mol Biol 2003; 329: 949-62.
184. [184] Sass P, Field J, Nikawa J, Toda T, et al. Cloning and characterization of the high-affinity cAMP phosphodiesterase of Saccharomyces cerevisiae. Proc Natl Acad Sci USA 1986; 83: 9303-7.
185. [185] Nikawa J, Cameron S, Toda T, et al. Rigorous feedback control of cAMP levels in Saccharomyces cerevisiae. Genes Dev 1987; 1: 931-7.
186. [186] Bahn YS, Staab J, Sundstrom P. Increased high-affinity phosphodiesterase PDE2 gene expression in germ tubes counteracts CAP1-dependent synthesis of cyclic AMP, limits hypha production and promotes virulence of Candida albicans. Mol Microbiol 2003; 50: 391-409.
187. [187] Jung WH, Stateva LI. The cAMP phosphodiesterase encoded by CaPDE2 is required for hyphal development in Candida albicans. Microbiology 2003; 149: 2961-76.
188. [188] Jung W, Jung S. Effects of pioglitazone and insulin on tight glycaemic control assessed by the continuous glucose monitoring system: A monocentric, parallel-cohort study. Clin Drug Investig 2005; 25: 347-52.
189. [189] Bahn Y S, Molenda M, Staab JF, et al. Genome-wide transcriptional profiling of the cyclic AMP-dependent signaling pathway during morphogenic transitions of Candida albicans. Eukaryot Cell 2007; 6: 2376-90.
190. [190] Daniels K J, Pujol C, Srikantha T, et al. The “finger, ” a unique multicellular morphology of Candida albicans induced by CO2 and dependent upon the Ras1-cyclic AMP pathway. Eukaryotic cell 2012; 11: 1257-67.
191. [191] Chandra J, Mukherjee P K, Leidich S D, et al. Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J Dent Res 2001; 80: 903-8.
192. [192] Ramage G, Vandewalle K, Wickes BL, et al. Characteristics of biofilm formation by Candida albicans. Rev Iberoam Micol 2001; 18: 163-70.
193. [193] Stephenson DT, Coskran TM, Wilhelms MB, et al. Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species. J Histochem Cytochem 2009; 57: 933-49.